Piperacillin
Historical source. Current clinical review is incomplete. This monograph will be updated in the future.
Piperacillin (opens in a new tab)Original source URL: https://globalrph.com/dilution/piperacillin/ | Retrieved 2026-11-04
Source dates, location and integrity
This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.
- Original source URL
- https://globalrph.com/dilution/piperacillin/ (opens in a new tab)
- Source date
- Not established in the retrieved source
- Retrieved
- 2026-11-04T19:47:11.367605+00:00
- Source location
- div.post-content
- Packaged content SHA-256
- 062caa0283a33d0a30a2c402866b14ced2d9b7121e3088ad39820d4aafa190d1
- Original response SHA-256
- 4c65f6a66772da671b2715c6f9c3cbd510a72d578b498c720dd40d5502e568ca
- Source body SHA-256
- a4121e174c845615b54ca64b71966fd397dbcef1cfe439cd8261991d06ca7797
Piperacillin |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Usual Diluents |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| D5W, NS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| [0 to 2 grams] [50 ml] [30 min] [Over 2 grams] [100 ml] [30 min] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stability / Miscellaneous |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EXP: 1 DAY (RT) / 7 DAYS (REF). Label: Refrigerate.
IM injection: Dissolve each gram with 2 ml. Maximum of 2 grams per injection site. (May use SW, BS-SW, NS, 0.5 to 1% lidocaine). Mild infection: 3-4g ivpb q6-8h DOSAGE AND ADMINISTRATION PIPRACIL should not be mixed with an aminoglycoside in a syringe or infusion bottle since this can result in inactivation of the aminoglycoside. The maximum daily dose for adults is usually 24 g/day, although higher doses have been used. Intramuscular injections (see NOTE) should be limited to 2 g per injection site. This route of administration has been used primarily in the treatment of patients with uncomplicated gonorrhea and urinary tract infections. DOSAGE RECOMMENDATIONS
The average duration of PIPRACIL treatment is from seven to ten days, except in the treatment of gynecologic infections, which is from three to ten days; the duration should be guided by the patient's clinical and bacteriological progress. For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for S. pyogenes infections should be maintained for at least ten days to reduce the risk of rheumatic fever. When PIPRACIL is given concurrently with aminoglycosides, both drugs should be used in full therapeutic doses. Renal Impairment Separate renal reference: Open Renal Dosing Master (opens in a new tab)
For patients on hemodialysis, the maximum daily dose is 6 g/day (2 g every 8 hours). In addition, because hemodialysis removes 30% to 50% of piperacillin in 4 hours, a 1-g additional dose should be administered following each dialysis period. For patients with renal failure and hepatic insufficiency, measurement of serum levels of piperacillin will provide additional guidance for adjusting dosage. Prophylaxis
Intravenous Administration DIRECTIONS FOR ADMINISTRATION Intravenous Injection (Bolus) -------------------------------------------------------------------------------- Intramuscular Administration Reconstitution Directions: DIRECTIONS FOR ADMINISTRATION The preferred site is the upper outer quadrant of the buttock (ie, gluteus maximus). The deltoid area should be used only if well-developed, and then only with caution to avoid radial nerve injury. Intramuscular injections should not be made into the lower or mid-third of the upper arm. Stability of PIPRACIL Following Reconstitution Pharmacy vials should be used immediately after reconstitution. Discard any unused portion after 24 hours if stored at room temperature (20° to 25°C [68° to 77°F]), or after 48 hours if stored at refrigerated temperature (2° to 8°C [36° to 46°F]). Vials should not be frozen after reconstitution. How Supplied Product Numbers Store at controlled room temperature 20°C-25°C(68°F-77°F). Wyeth® W10440C007 Source: [package insert] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||